Search research articles
Contact Us
Filters
Showing results (51-60 of 76) with videos related to
Page
of 8
Sort By:
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
December 18, 2017
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer
Madeleine T King, Martin R Stockler, Rachel L O'Connell, et al.
JAMA Network Open
|
August 26, 2024
Pregnancy-Related Factors and Breast Cancer Risk for Women Across a Range of Familial Risk
Jasmine A McDonald, Yuyan Liao, Julia A Knight, et al.
Breast Cancer Research and Treatment
|
November 27, 2008
Family history of breast cancer and all-cause mortality after breast cancer diagnosis in the Breast Cancer Family Registry
Ellen T Chang, Roger L Milne, Kelly-Anne Phillips, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 28, 2022
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study
Yeh Chen Lee, Madeleine T King, Rachel L O'Connell, et al.
Gynecologic Oncology
|
February 14, 2017
Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study
Phuong L Mai, Marion Piedmonte, Paul K Han, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes
Lucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
Gynecologic Oncology
|
June 19, 2022
Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer
Rachel Campbell, Daniel S J Costa, Martin R Stockler, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 22, 2024
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes
Lucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
International Journal of Cancer
|
February 7, 2019
Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort
Nur Zeinomar, Kelly-Anne Phillips, Mary B Daly, et al.
Obstetrics and Gynecology
|
January 12, 2019
Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma
Peter G Rose, James J Java, Ritu Salani, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 76) with videos related to
Sort By:
Page
of 8
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
December 18, 2017
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer
Madeleine T King, Martin R Stockler, Rachel L O'Connell, et al.
JAMA Network Open
|
August 26, 2024
Pregnancy-Related Factors and Breast Cancer Risk for Women Across a Range of Familial Risk
Jasmine A McDonald, Yuyan Liao, Julia A Knight, et al.
Breast Cancer Research and Treatment
|
November 27, 2008
Family history of breast cancer and all-cause mortality after breast cancer diagnosis in the Breast Cancer Family Registry
Ellen T Chang, Roger L Milne, Kelly-Anne Phillips, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 28, 2022
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study
Yeh Chen Lee, Madeleine T King, Rachel L O'Connell, et al.
Gynecologic Oncology
|
February 14, 2017
Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study
Phuong L Mai, Marion Piedmonte, Paul K Han, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes
Lucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
Gynecologic Oncology
|
June 19, 2022
Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer
Rachel Campbell, Daniel S J Costa, Martin R Stockler, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 22, 2024
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes
Lucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
International Journal of Cancer
|
February 7, 2019
Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort
Nur Zeinomar, Kelly-Anne Phillips, Mary B Daly, et al.
Obstetrics and Gynecology
|
January 12, 2019
Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma
Peter G Rose, James J Java, Ritu Salani, et al.
Page
of 8